You are here: Industry Insights > Takeda

News List

Novavax partners with Takeda to develop Covid-19 vaccine in Japan pharmaceutical-technology
August 11, 2020
US-based biotechnology firm Novavax has partnered with Takeda Pharmaceutical to develop, manufacture and commercialise its Covid-19 vaccine candidate, NVX‑CoV2373, in Japan.
AbbVie, Amgen and Takeda jointly study impact of anti-inflammatory drugs in COVID-19 treatment expresspharma
August 04, 2020
I-SPY COVID will evaluate the impact of cenicriviroc, Otezla, and Firazyr on inflammatory response in severely ill, hospitalised COVID-19 patients.
Teva-Takeda joint venture divests certain assets in Japan to Nichi-Iko pharmaceutical-technology
August 03, 2020
A business joint venture (BV) comprising Teva Pharmaceutical and Takeda Pharmaceutical in Japan is set to divest the majority of its generic and operational assets to Nichi-Iko Pharmaceutical.
US FDA grants Breakthrough Therapy Designation for Takeda’s Pevonedistat expresspharma
August 03, 2020
The investigational drug is for the treatment of patients with higher-risk myelodysplastic syndromes (HR-MDS).
NICE backing for Takeda's Adcetris for rare lymphoma pharmatimes
July 14, 2020
Takeda's Adcetris (brentuximab vedotin) has won the backing of the National Institute for Health and Care Excellence (NICE) as a treatment for untreated systemic anaplastic large cell lymphoma (sALCL), a rare type of lymphoma.
Carmine, Takeda Collaborate to Discover and Develop Rare Disease Gene Therapies americanpharmaceuticalreview
July 09, 2020
Carmine Therapeutics has signed a research collaboration agreement with Takeda to discover, develop and commercialize non-viral gene therapies for two rare disease targets using Carmine's REGENT technology, based on red blood cell extracellular vesicles.
Takeda launches IBD medication Kynteles in India expresspharma
July 09, 2020
Used to treat Ulcerative Colitis and Crohn's Disease as well, the drug expands the company’s GI portfolio in the country.
Takeda forms $900m research alliance with Carmine Therapeutics pharmaceutical-technology
July 01, 2020
Japanese pharmaceutical giant Takeda Pharmaceutical has entered into a research collaboration agreement with US-based Carmine Therapeutics for the discovery, development and commercialisation of rare disease therapies.
Neurocrine Licenses Seven Takeda Compounds in $2B Deal contractpharma
June 22, 2020
To develop and commercialize early-to-mid-stage psychiatry pipeline including assets for for schizophrenia, treatment-resistant depression and anhedonia.
Takeda licences psychiatry programmes to Neurocrine Biosciences pharmaceutical-technology
June 18, 2020
Takeda Pharmaceutical has collaborated with US-based Neurocrine Biosciences for the development and commercialisation of therapeutic compounds in its early-to-mid-stage psychiatry pipeline.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page